Cancer Articles, News & Research Info | Treatment & Drug Trials - Cancer Therapy Advisor

Featured

More Features

Despite a challenging toxicity profile, high dose interleukin-2 (HD IL-2), one of the earliest-approved immunotherapies for metastatic renal cell carcinoma still has a role in treating selected patients, a new registry analysis shows.

IL-2 and Metastatic Renal Cell Carcinoma

Despite a challenging toxicity profile, high dose interleukin-2 (HD IL-2), one of the earliest-approved immunotherapies for metastatic renal cell carcinoma still has a role in treating selected patients, a new registry analysis shows.

More  »